...
首页> 外文期刊>European Journal of Pharmacology: An International Journal >Urine osmolality, cyclic AMP and aquaporin-2 in urine of patients under lithium treatment in response to water loading followed by vasopressin administration.
【24h】

Urine osmolality, cyclic AMP and aquaporin-2 in urine of patients under lithium treatment in response to water loading followed by vasopressin administration.

机译:锂治疗患者的尿液渗透压,环状AMP和aquaporin-2对水负荷后加压素的反应对锂的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

Lithium is the drug that is most frequently associated with acquired nephrogenic diabetes insipidus (NDI). The exact mechanism of lithium-induced NDI in man is unknown. The aim of the present study was to investigate the kidney response to minimal and maximal stimulation of the kidney urine concentrating mechanism by measuring urine osmolality, and urine levels of cAMP and AQP-2 in urine of patients under long-term lithium treatment. Twenty patients under long-term lithium treatment were included. The kidney urinary 3',5'-cyclic adenosine monophosphate (cyclic AMP), aquaporin-2 levels and urine osmolality were determined during a situation of minimal kidney urine concentrating activity (induced by water loading) and during a situation following maximal stimulation of kidney urine concentrating activity (induced by 1-desamino-8-D-arginine-vasopressin). Patients were classified as NDI, partial NDI and non-NDI based on maximal reached urine osmolality. The partial correlation (r) between urinary cyclic AMP levels (mol/l) and urine osmolality was 0.94 (P<0.001). No significant correlation was observed between urinary aquaporin-2 levels (mol/mol creatinine) and osmolality nor between urinary cyclic AMP and aquaporin-2 levels. The rise in urinary cyclic AMP but not aquaporin-2 levels upon 1-desamino-8-D-arginine-vasopressin administration after water loading significantly differed between the three categories, decreasing with increasing NDI category. In conclusion we found that in lithium-induced kidney urine concentrating deficit in man, the cyclic AMP generation in response to 1-desamino-8-D-arginine-vasopressin administration after water loading, is impaired. It remains to be elucidated whether principal cells, G-proteins or adenylate cyclase e.g. are the major targets for the mechanism underlying lithium-induced NDI in man.
机译:锂是最常与获得性肾原性尿崩症(NDI)相关的药物。锂诱导人体内NDI的确切机制尚不清楚。本研究的目的是通过测量长期接受锂治疗的患者尿液渗透压和尿液中cAMP和AQP-2的尿液浓度,来研究肾脏对肾脏尿液浓缩机制的最小和最大刺激的反应。包括接受长期锂治疗的20名患者。在最小的肾脏尿浓缩活动(由水负荷引起)的情况下以及在最大程度刺激肾脏后的情况下,测定了肾脏尿液中的3',5'-环磷酸腺苷(环AMP),水通道蛋白2水平和尿渗透压尿液浓缩活性(由1-desamino-8-D-精氨酸-加压素诱导)。根据最大尿渗透压,将患者分为NDI,部分NDI和非NDI。尿环AMP水平(mol / l)与尿渗透压之间的部分相关性(r)为0.94(P <0.001)。尿中aquaporin-2水平(mol / mol肌酐)与重量克分子渗透压浓度之间以及尿环AMP和aquaporin-2水平之间均无显着相关性。在三类之间,水负荷后施用1-desamino-8-D-精氨酸-加压素后,尿中环AMP的升高,但aquaporin-2的水平没有显着差异,随NDI类别的增加而降低。总之,我们发现,在锂诱导的人肾脏尿液浓缩不足中,水负荷后响应1-desamino-8-D-精氨酸-加压素的循环AMP生成受到损害。是否要阐明主要细胞,G蛋白或腺苷酸环化酶,例如是锂诱导人体内NDI的潜在机制的主要目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号